Rallybio (RLYB) Current Assets (2020 - 2026)
Rallybio (RLYB) posted Current Assets of $53.5 million for Q1 2026, down 12.67% sequentially from $61.3 million in Q4 2025, and down 6.78% YoY from $57.4 million in Q1 2025.
Rallybio (RLYB) Current Assets (2020 - 2026) Analysis & Trends
Rallybio has reported Current Assets for 7 years, with the latest figure at $53.5 million in Q1 2026.
- Quarterly Current Assets fell 6.78% year-over-year to $53.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.5 million (down 6.78% YoY) and the FY2025 annual result came in at $61.3 million, down 9.71% from the prior year.
- Current Assets eased to $53.5 million in Q1 2026 per RLYB's latest filing, from $61.3 million in the prior quarter.
- Over five years, Current Assets peaked at $179.5 million in Q4 2022 and troughed at $50.3 million in Q2 2025.
- A 5-year average of $107.3 million and a median of $98.5 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2025: Current Assets soared 30.29% in 2022, then slumped 45.03% in 2025.
- Over 5 years, Current Assets stood at $179.5 million in 2022, then plunged by 36.05% to $114.8 million in 2023, then sank by 40.9% to $67.8 million in 2024, then retreated by 9.71% to $61.3 million in 2025, then declined by 12.67% to $53.5 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $53.5 million, $61.3 million, and $66.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 97.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.25 Mn |
| Mar 31, 2026 | 53.49 Mn |
| Dec 31, 2025 | 61.25 Mn |
| Sep 30, 2025 | 66.63 Mn |
| Jun 30, 2025 | 50.27 Mn |
| Mar 31, 2025 | 57.38 Mn |
| Dec 31, 2024 | 67.84 Mn |
| Sep 30, 2024 | 78.23 Mn |
| Jun 30, 2024 | 91.44 Mn |
| Mar 31, 2024 | 98.55 Mn |
| Dec 31, 2023 | 114.79 Mn |
| Sep 30, 2023 | 132.42 Mn |
| Jun 30, 2023 | 146.83 Mn |
| Mar 31, 2023 | 161.28 Mn |
| Dec 31, 2022 | 179.50 Mn |
| Sep 30, 2022 | 142.43 Mn |
| Jun 30, 2022 | 154.30 Mn |
| Mar 31, 2022 | 167.78 Mn |
| Dec 31, 2021 | 180.87 Mn |
| Sep 30, 2021 | 192.39 Mn |